Alloy GLP-1 at a glance: A midlife-women-only GLP-1 telehealth platform built around the hormonal context of perimenopause + menopause. Co-founded by Anne Fulenwider (former Marie Claire editor-in-chief) and Monica Molenaar. Named menopause-specialist medical board including Menopause Society Certified Practitioners. Hybrid GLP-1 menu: cash-pay Compounded Semaglutide / Tirzepatide via FDA-registered 503A / 503B partners + FDA-approved Wegovy / Zepbound via insurance. 1:1 lifestyle coaching bundled (registered dietitians + certified health coaches). Women-only patient base. HSA/FSA accepted. Broader Alloy menopause ecosystem (HRT + vaginal health + skin + sleep + sexual health). Mainstream press: NYT + WSJ + Forbes + Vogue + Bloomberg. Best for midlife women (40+) navigating perimenopausal or menopausal weight management who want named-founder + menopause-specialist context + bundled coaching. Skip if you're male, you want flat-rate compounded-only pricing, or you want a non-women-focused platform.
✓ Pick Alloy GLP-1 if
You are a midlife woman (40+) in perimenopause or menopause wanting GLP-1 weight management prescribed within the context of your hormonal transition; you value named founders (Anne Fulenwider + Monica Molenaar) and named menopause-specialist clinicians; you want bundled 1:1 coaching from registered dietitians or certified health coaches; you appreciate a hybrid GLP-1 model (compounded cash-pay + FDA-approved branded via insurance); you want HSA/FSA eligibility; you value the broader Alloy menopause ecosystem (HRT + vaginal health + skin + sleep + sexual health); you appreciate NYT + WSJ + Forbes + Vogue + Bloomberg mainstream press validation.
✕ Skip Alloy GLP-1 if
You are male (Alloy is a women-only clinical platform); you want flat-rate compounded-only pricing with no membership / coaching wrap; you don't want a menopause-contextualized clinical model; you require specific named compounding pharmacy disclosed upfront on the landing page; you have GLP-1 contraindications; or you live in a state where Alloy is not currently licensed (check eligibility during intake).
Our verdict on Alloy GLP-1
- Best for
- Midlife women (40+) navigating perimenopause or menopause who want GLP-1 weight management within the context of hormonal transition + named menopause-specialist medical board + bundled lifestyle coaching.
- GLP-1 strengths
- Midlife-women-only clinical positioning recognizing the unique metabolic challenges of the perimenopausal + menopausal hormonal transition (weight redistribution, insulin sensitivity changes, sleep disruption, mood shifts); co-founders Anne Fulenwider (former Marie Claire editor-in-chief) and Monica Molenaar with public press footprint; named menopause-specialist medical board including Menopause Society Certified Practitioners; hybrid GLP-1 model — cash-pay Compounded Semaglutide / Tirzepatide via FDA-registered Section 503A / 503B partners + FDA-approved branded Wegovy / Zepbound coordinated through commercial insurance; bundled 1:1 lifestyle coaching from registered dietitians + certified health coaches; women-only patient base making the clinical context uniformly midlife-female; broader Alloy menopause ecosystem (HRT + vaginal health + skin care + sleep + sexual health); mainstream press validation NYT + WSJ + Forbes + Vogue + Bloomberg; comprehensive Privacy Policy + Terms of Service + Telehealth Consent + HIPAA Notice of Privacy Practices; HSA/FSA accepted at checkout; published customer reviews + testimonials from menopause-age members.
- GLP-1 drawbacks
- Women-only clinical model — not for men; specific named compounding pharmacy partner not surfaced on landing page; specific per-medication GLP-1 pricing surfaces post-intake rather than published upfront; FDA-approved branded GLP-1 access depends on individual insurance benefits; compounded GLP-1 disclosure applies; state-availability subject to licensure rules; not the cheapest possible compounded GLP-1 if you only want medication without bundled coaching.
- GLP-1 pricing
- Membership + medication. Compounded path is cash-pay; FDA-approved branded path is insurance-coordinated. Specific pricing surfaces post-intake. HSA/FSA accepted.
- Editor's rating
- 4.4 / 5 — Distinctive positioning: midlife-women clinical context + named menopause-specialist medical board + bundled coaching + hybrid compounded / FDA-approved GLP-1 menu + mainstream press validation.
Start Alloy's GLP-1 program today
Founded Fulenwider + Molenaar. Named menopause-specialist medical board. Hybrid compounded + FDA-approved GLP-1. Bundled coaching. HSA/FSA accepted.
Visit Alloy's Official Site →The named co-founders
Anne Fulenwider
Co-Founder & Co-CEOFormer editor-in-chief of Marie Claire and Brides magazines. Spent two decades at the helm of major mainstream women's publications before co-founding Alloy to address the under-served midlife women's health market. Public press footprint across NYT, WSJ, Forbes, Vogue, Bloomberg.
Monica Molenaar
Co-Founder & Co-CEOCo-founder of Alloy Women's Health. Public advocate for evidence-based midlife women's health care including hormone replacement therapy (HRT), weight management, and perimenopausal / menopausal care. Mainstream press footprint.
Named-founder transparency is editorially material — it provides an accountability anchor that anonymous-founder consumer telehealth platforms lack. Both Fulenwider and Molenaar are public-facing executives with traceable press histories.
Why menopause context matters for GLP-1
The perimenopausal and menopausal transition introduces several metabolic shifts that affect how GLP-1 protocols should be sequenced:
- Weight redistribution: Estrogen decline drives a shift from gluteofemoral fat storage to visceral adiposity, even at the same total body weight.
- Insulin sensitivity: Declining estrogen reduces insulin sensitivity, raising baseline fasting glucose and HbA1c in many women.
- Sleep disruption: Hot flashes + sleep fragmentation interact with GLP-1's appetite + reward pathway effects.
- Mood + cognition: Mood shifts during perimenopause interact with GLP-1's emerging cognitive effects.
- HRT interaction: Many midlife women are on or considering hormone replacement therapy — Alloy's integrated platform can coordinate GLP-1 with HRT decisions.
Most consumer GLP-1 platforms prescribe without this context. Alloy's named menopause-specialist medical board is structured to factor these dimensions into the protocol.
What we verified about Alloy GLP-1
| What we checked | What we found |
|---|---|
| Brand & entity VERIFIED | Alloy Women's Health · © 2026 All rights reserved |
| Domain VERIFIED | myalloy.com |
| Co-Founder & Co-CEO Anne Fulenwider VERIFIED | Former editor-in-chief of Marie Claire and Brides magazines |
| Co-Founder & Co-CEO Monica Molenaar VERIFIED | Public press footprint in midlife women's health |
| Named menopause-specialist medical board VERIFIED | Including Menopause Society Certified Practitioners |
| Hybrid GLP-1 menu VERIFIED | Compounded (cash-pay) + FDA-approved branded (insurance) |
| Compounded Semaglutide path VERIFIED | FDA-registered 503A / 503B partner pharmacy |
| Compounded Tirzepatide path VERIFIED | FDA-registered 503A / 503B partner pharmacy |
| FDA-approved Wegovy VERIFIED | Insurance-coordinated path |
| FDA-approved Zepbound VERIFIED | Insurance-coordinated path |
| Bundled 1:1 lifestyle coaching VERIFIED | Registered dietitians + certified health coaches |
| Women-only patient base VERIFIED | Clinical model designed for midlife women |
| Broader Alloy menopause ecosystem VERIFIED | HRT + vaginal health + skin + sleep + sexual health |
| Mainstream press validation VERIFIED | NYT + WSJ + Forbes + Vogue + Bloomberg |
| HSA/FSA eligible VERIFIED | Accepted at checkout |
| Customer reviews + testimonials VERIFIED | Published from menopause-age members |
| Privacy Policy + Terms + Telehealth Consent + HIPAA Notice VERIFIED | Comprehensive published |
| Specific named compounding pharmacy partner CAUTION | 503A / 503B framework disclosed; specific name not on landing page |
| Specific per-medication GLP-1 pricing upfront CAUTION | Surfaces during intake |
| State availability CAUTION | Subject to state-specific licensure; check during intake |
| Compounded GLP-1 disclosure CAUTION | "Compounded products are not approved nor evaluated for safety, efficacy, or quality by the FDA" |
All claims verified on myalloy.com as of June 2026. Alloy's combination of named co-founders + named menopause-specialist medical board + midlife-women clinical positioning + hybrid GLP-1 menu + bundled coaching + mainstream press is editorially distinctive.
Are Alloy's GLP-1 medications compounded or FDA-approved?
Alloy operates a hybrid model. The compounded path includes Compounded Semaglutide and Compounded Tirzepatide dispensed by FDA-registered Section 503A / 503B compounding pharmacy partners (cash-pay). The FDA-approved branded path includes Wegovy (semaglutide) and Zepbound (tirzepatide) coordinated through the member's commercial insurance.
The Alloy clinician determines which path is medically appropriate based on the member's BMI, comorbidities, and menopausal status. Standard disclosure applies to the compounded path: "Compounded products are not approved nor evaluated for safety, efficacy, or quality by the FDA."
The 2026 GLP-1 regulatory landscape
The FDA resolved the official semaglutide GLP-1 shortage in early 2025. Per FDA compounding guidance, mass compounding of essentially identical copies of commercially available drugs is generally restricted outside narrow patient-specific exceptions. Alloy's hybrid model — combining cash-pay compounded with insurance-coordinated FDA-approved branded — provides structural redundancy if compounded availability tightens.
Alloy GLP-1 pros and cons
✓What we like
- Midlife-women-only clinical positioning — perimenopause + menopause context
- Named co-founders: Anne Fulenwider (former Marie Claire EIC) + Monica Molenaar
- Named menopause-specialist medical board with Menopause Society Certified Practitioners
- Hybrid GLP-1 model: cash-pay compounded + insurance-coordinated FDA-approved branded
- Bundled 1:1 lifestyle coaching from registered dietitians + certified health coaches
- Women-only patient base — uniformly midlife-female clinical context
- Broader Alloy menopause ecosystem: HRT + vaginal health + skin care + sleep + sexual health
- HSA/FSA eligible at checkout
- Mainstream press validation: NYT + WSJ + Forbes + Vogue + Bloomberg
- Published customer reviews + testimonials from menopause-age members
- Comprehensive Privacy Policy + Terms + Telehealth Consent + HIPAA Notice of Privacy Practices
✕Where Alloy GLP-1 falls short
- Women-only clinical model — not for men
- Specific named compounding pharmacy partner not surfaced on landing page
- Specific per-medication GLP-1 pricing surfaces post-intake rather than published upfront
- FDA-approved branded GLP-1 access depends on individual insurance benefits
- State-availability subject to licensure rules
- Not the cheapest standalone compounded GLP-1 if you only want medication without the bundled coaching wrap
- Compounded GLP-1 disclosure applies
Start with Alloy today
Midlife-women-focused. Founded Fulenwider + Molenaar. Menopause-specialist medical board. Hybrid compounded + FDA-approved GLP-1. Bundled coaching.
Visit Alloy's Official Site →Alloy GLP-1 sign-up & ongoing-care checklists
Before sign-up
- Confirm midlife / menopause stage — Alloy is designed for women 40+.
- Review named founders + medical board.
- Check state eligibility via intake.
- Gather BMI + weight history + HRT status.
- Decide insurance vs cash-pay preference.
- Read Terms + Telehealth Consent.
- Complete intake at myalloy.com/weight.
After sign-up
- Meet menopause-specialist clinician via video.
- Determine compounded vs FDA-approved path.
- Meet your dietitian / coach.
- Receive GLP-1 medication (compounded → 503A/503B pharmacy; FDA-approved → insurance).
- Coordinate with HRT if applicable.
- Attend bundled 1:1 coaching sessions.
- Track progress + symptoms via the Alloy platform.
Canceling Alloy
- Review Terms of Service.
- Contact Member Support or use account dashboard.
- Cancel a few days before billing.
- Request written confirmation.
- Discuss GLP-1 off-ramp with menopause clinician — don't dispose of medication abruptly.
- Coordinate HRT continuation separately if relevant.
Alloy GLP-1 frequently asked questions
How much does Alloy's GLP-1 program cost in 2026?
Membership + medication. Compounded path is cash-pay; FDA-approved branded path is insurance-coordinated. Specific pricing surfaces post-intake. HSA/FSA accepted. Bundled 1:1 coaching included.
Is Alloy's GLP-1 program legit?
Yes — named co-founders Anne Fulenwider + Monica Molenaar. Named menopause-specialist medical board including Menopause Society Certified Practitioners. NYT, WSJ, Forbes, Vogue, Bloomberg mainstream press validation. Published Privacy Policy + Terms + Telehealth Consent + HIPAA Notice of Privacy Practices.
What GLP-1 medications does Alloy offer?
Hybrid: cash-pay Compounded Semaglutide + Compounded Tirzepatide (FDA-registered 503A / 503B partners) plus FDA-approved branded Wegovy + Zepbound coordinated through insurance.
Who founded Alloy?
Anne Fulenwider (former editor-in-chief of Marie Claire and Brides) and Monica Molenaar co-founded Alloy Women's Health to address the under-served midlife women's health market.
What makes Alloy different from other GLP-1 platforms?
Midlife-women-only clinical model with menopause-specialist medical board. Recognizes the unique metabolic challenges of perimenopause + menopause that affect GLP-1 protocols.
What is included in the Alloy Weight Loss membership?
Medical care with menopause-specialist clinicians + 1:1 lifestyle coaching (registered dietitians + certified health coaches) + ongoing follow-ups + integration with broader Alloy menopause ecosystem.
Does Alloy work with insurance?
For FDA-approved branded GLP-1 (Wegovy, Zepbound), Alloy coordinates with commercial insurance. Coverage depends on plan benefits and prior authorization. Compounded path is cash-pay. HSA/FSA accepted.
Is Alloy available in all U.S. states?
Most U.S. states, subject to state-specific licensure rules. Check eligibility at myalloy.com/weight intake. Women-only platform.
How do I cancel Alloy's Weight Loss membership?
Via account dashboard or Member Support. Cancel a few days before next billing. Discuss GLP-1 off-ramp with your clinician.
Are Alloy's GLP-1 medications compounded or FDA-approved?
Both. Hybrid model: compounded cash-pay via FDA-registered 503A / 503B partners + FDA-approved branded Wegovy / Zepbound via insurance. "Compounded products are not approved nor evaluated for safety, efficacy, or quality by the FDA."
Honest verdict — should you choose Alloy?
Alloy earns its 4.4/5 GLP-1 editor's rating on five distinctive features. First: midlife-women-only clinical positioning that recognizes the unique metabolic challenges of the perimenopausal + menopausal hormonal transition — most GLP-1 platforms treat all adults uniformly. Second: named co-founders Anne Fulenwider (former Marie Claire editor-in-chief) and Monica Molenaar with public press footprint. Third: named menopause-specialist medical board including Menopause Society Certified Practitioners — specialty-board credentialing tied directly to GLP-1 prescribing within a hormonal context. Fourth: bundled 1:1 lifestyle coaching from registered dietitians and certified health coaches — not just medication. Fifth: hybrid GLP-1 model (cash-pay compounded + insurance-coordinated FDA-approved branded) within an integrated midlife women's health ecosystem (HRT + vaginal health + skin care + sleep + sexual health).
The bottom line
If you are a midlife woman (40+) navigating perimenopause or menopause and want GLP-1 weight management prescribed within the context of your hormonal landscape — and you value named founders + named menopause-specialist clinicians + bundled coaching + mainstream press validation — Alloy is editorially distinctive. If you are male, want flat-rate compounded-only pricing, or want a non-women-focused platform, the model is not the right fit.
Start with Alloy today
Midlife women. Menopause-aware. Founded Fulenwider + Molenaar. Hybrid GLP-1.
Visit Alloy's Official Site →Published: June 11, 2026 · Verified: June 2026 · Spot a factual issue? Tell our editors.